🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 15 of 55

  1. Cemiplimab-Rwlc

    Regeneron UK Limited

    Cutaneous Squamous Cell Carcinoma

    phase 2 small molecule terminated

    2 trials

  2. Cemiplimab-Rwlc

    Regeneron UK Limited

    Non-small Cell Lung Cancer Stage III

    phase 2 small molecule active

    1 trial

  3. Ceralasertib

    United Therapeutics Europe Ltd

    Gynaecological Cancers

    phase 2 small molecule active

    1 trial

  4. Ceritinib (LDK378)

    Novartis Pharmaceuticals

    Tumors With Aberrations in ALK

    phase 2 small molecule terminated

    1 trial

  5. Cetrelimab

    Janssen Cilag International NV

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  6. Cetuximab

    Solid Biosciences

    Head and Neck Neoplasm

    phase 2 small molecule completed

    1 trial

  7. Cetuximab

    Hoffmann-La Roche

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  8. Cetuximab

    Merck KGaA, Darmstadt, Germany

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  9. Cetuximab β；Fruquintinib；

    Zhejiang University

    Colorectal Neoplasms

    phase 2 small molecule active

    1 trial

  10. Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin

    Hospital Authority, Hong Kong

    Stomach Neoplasms

    phase 2 small molecule active

    1 trial

  11. ChAdOx1-MVA 5T4 vaccine

    Barinthus Biotherapeutics plc.

    Intermediate Risk Prostate Cancer

    phase 2 mab terminated

    1 trial

  12. ChAdOx1-PCAQ

    Barinthus Biotherapeutics plc.

    Prostate Cancer

    phase 2 mab terminated

    1 trial

  13. Chemotherapy + immunotherapy

    Hunan Province Tumor Hospital

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  14. Chemotherapy plus apatinib

    Lei Li

    Recurrent Cervical Carcinoma

    phase 2 small molecule completed

    1 trial

  15. Chemotherapy+PD-1 inhibitor+8Gy x 3f

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HR+HER2- Breast Cancer

    phase 2 small molecule active

    1 trial

  16. Chidamide

    Biotech Pharmaceutical Co.,

    Relapsed or Refractory Peripheral T-cell Lymphoma

    phase 2 small molecule active

    1 trial

  17. Chidamide

    Sun Yat-sen University

    Peripheral T-cell Lymphoma

    phase 2 small molecule active

    1 trial

  18. Chidamide

    Biotech Pharmaceutical Co.,

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule terminated

    1 trial

  19. Chidamide

    The First People's Hospital of Lianyungang

    Neuroendocrine Tumors

    phase 2 small molecule active

    2 trials

  20. Chidamide + Tislelizumab + chemotherapy (CapeOX )

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colon Adenocarcinoma

    phase 2 small molecule active

    1 trial

  21. Chidamide Tablets； PD-L1 Inhibitor (as per chosen drug's prescribing information)；Carboplatin； Etoposide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  22. Chidamide combined with Duvillisib

    The First People's Hospital of Lianyungang

    Peripheral T Cell Lymphoma

    phase 2 small molecule active

    1 trial

  23. Chinese Medicine Oral Rinse Formula-I (CMORF-I)

    Chinese University of Hong Kong

    Head and Neck Neoplasms

    phase 2 small molecule active

    1 trial

  24. Chlorambucil

    Teva Pharma GmbH

    Chronic Lymphocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  25. Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety, tolerability, pharmacokinetics, and anti-tumor activity of novel therapeutics in patients with early relapsed metastatic triple-negative breast cancer

    The George Institute

    Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ or IHC 2+/ISH-) breast cancer with early relapse while on (neo) adjuvant systemic treatment or within 12 months from the end of all treatments with curative intent.

    phase 2 other active

    1 trial

  26. Cholecalciferol

    Hospital Authority, Hong Kong

    Hematologic Neoplasms

    phase 2 small molecule active

    1 trial

  27. Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  28. Cisplatin

    Ultragenyx UK Limited

    Squamous Cell Carcinoma of the Anus

    phase 2 small molecule active

    1 trial

  29. Cisplatin Accord Healthcare 1 mg/ml concentraat voor oplossing voor infusie, Carboplatin Accord Healthcare 10 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    Vulvar cancer

    phase 2 small molecule active

    1 trial

  30. Cisplatin and Doxorubicin

    Chinese University of Hong Kong

    Gastric Cancer Peritoneal Metastases

    phase 2 small molecule active

    1 trial

  31. Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Uterine Cervical Neoplasm

    phase 2 small molecule active

    1 trial

  32. Cisplatin+Capecitabine+Sintilimab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  33. Clifutinib Besylate

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Acute Myeloid Leukemia, Adult

    phase 2 small molecule active

    1 trial

  34. Clobetasol Propionate

    United Therapeutics Europe Ltd

    Colon Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  35. Clostridium Butyricum Tablets

    The First People's Hospital of Lianyungang

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 2 small molecule active

    1 trial

  36. Cobimetinib

    Hoffmann-La Roche

    Solid Tumors

    phase 2 small molecule completed

    1 trial

  37. Colonoscopy with enhanced dye

    Cardiff Oncology

    Colorectal Cancer

    phase 2 other completed

    1 trial

  38. Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Breyanzi 1.1-70 × 106 cells/mL / 1.1-70 × 106 cells/mL dispersion for infusion, YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion

    The George Institute

    relapsed/refractory Large B-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  39. Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Maplirpacept

    Pfizer Australia Pty Ltd

    Relapsed/Refractory Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  40. Columvi 10 mg concentrate for solution for infusion, Glofitamab, Gazyvaro 1,000 mg concentrate for solution for infusion., RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)

    phase 2 small molecule active

    1 trial

  41. Combination of Bortezomib, Fludarabine and Cyclophosphamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mantle Cell Lymphoma Recurrent

    phase 2 small molecule active

    1 trial

  42. Combination of MK3475 with Metronomic CP

    Lxo Ireland Designated Activity Company

    Sarcoma

    phase 2 small molecule completed

    1 trial

  43. Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)

    United Therapeutics Europe Ltd

    Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  44. Combination therapy (COMB)

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule active

    1 trial

  45. Combinations

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  46. Conventional Roux-en-Y Gastrojejunostomy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  47. Coriolus Versicolor

    Hospital Authority, Hong Kong

    Carcinoma

    phase 2 small molecule terminated

    1 trial

  48. Cotellic 20 mg film-coated tablets, Ginisortamab

    Ningbo Cancer Hospital

    Metastatic pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.